Hu Yinin, Krumeich Lauren N, Fisher Sarah B, Javid Mahsa, Kuo Jennifer H, Wachtel Heather
University of Maryland Baltimore, Baltimore, MD, USA.
University of Michigan, Ann Arbor, MI, USA.
Ann Surg Oncol. 2025 May 29. doi: 10.1245/s10434-025-17498-0.
Treatment pathways for low-risk thyroid cancer have seen broad de-escalation over the past two decades. A condition once treated predominantly with total thyroidectomy with selective adjuvant radioactive iodine is now frequently treated with partial thyroidectomy alone or even active surveillance among carefully selected patients. Over the same period, percutaneous ablative treatment for benign thyroid nodules has expanded. Inevitably, there evolved a growing interest in the application of ablative therapy to lowrisk thyroid cancer as an intermediate option between surveillance and resection. This article introduces the most common modalities for percutaneous ablation of thyroid cancer, summarizes contemporary evidence, highlights gaps in knowledge, and proposes a set of real-world practice recommendations.
在过去二十年中,低风险甲状腺癌的治疗路径已大幅简化。一种曾经主要通过全甲状腺切除术加选择性辅助放射性碘治疗的疾病,现在经常仅通过部分甲状腺切除术治疗,甚至在经过精心挑选的患者中进行主动监测。同期,经皮消融治疗良性甲状腺结节的应用有所扩大。不可避免地,人们越来越关注将消融治疗应用于低风险甲状腺癌,作为监测和切除之间的一种中间选择。本文介绍了甲状腺癌经皮消融的最常见方式,总结了当代证据,突出了知识空白,并提出了一套实际操作建议。